<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02025634</url>
  </required_header>
  <id_info>
    <org_study_id>503526</org_study_id>
    <nct_id>NCT02025634</nct_id>
  </id_info>
  <brief_title>Intravenous Acetaminophen for Non-Narcotic Postoperative Pain Management Following Knee Arthroscopy</brief_title>
  <acronym>IVTYLENOL</acronym>
  <official_title>Determining the Efficacy of Intravenous Acetaminophen as a Non-Narcotic Postoperative Pain Management Technique Following Knee Arthroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AdventHealth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Central Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AdventHealth</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, placebo controlled, single blind study is to determine if&#xD;
      postoperative pain levels, as measured by a verbal numeric pain rating scale (VNRS), are&#xD;
      reduced with the administration of IV acetaminophen when compared to a control group.&#xD;
      Particular focus will be on the postoperative opioid consumption. In addition, we will&#xD;
      ascertain if the total time the participant is in the PACU differs in those who receive the&#xD;
      IV acetaminophen versus those who do not.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo controlled, single blind study of intravenous (IV)&#xD;
      acetaminophen in a postoperative arthroscopy patient population. Although use of this&#xD;
      medication as a non-narcotic analgesia has been validated in other patient populations such&#xD;
      as post operative pelvic and abdominal surgeries, it has not been demonstrated in those who&#xD;
      have recently undergone knee arthroscopy with or without chondroplasty. In this study all&#xD;
      participants will be injected with a standard of care intra-articular dose of ropivacaine&#xD;
      HCl, .2% (Naropin) prior to transfer to the Post Anesthesia Care Unit (PACU). Each will be&#xD;
      randomized 1:1 to receive IV acetaminophen in 100ml of 0.9% NS (treatment group) or a 100 ml&#xD;
      0.9 % NS placebo (control).&#xD;
&#xD;
      The PACU nursing staff will periodically ascertain the participants' pain scores on a 0-10&#xD;
      scale. All other pain medication or related treatment will be recorded. Statistical analysis&#xD;
      will be done to determine if there is a difference in pain scores between the treatment&#xD;
      versus control group. Further evaluation will examine if opioid consumption and total time in&#xD;
      PACU differs between groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Pain Levels</measure>
    <time_frame>up to 8 hours</time_frame>
    <description>To determine if postoperative pain levels, as measured by a Verbal Numerical Rating Scale (VNRS), are reduced with the administration of IV acetaminophen when compared to a control group. In the VNRS, the user has the option to verbally rate their scale from 0 to 10. Zero indicates the absence of pain, while 10 represents the most intense pain possible.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Opioid Consumption</measure>
    <time_frame>up to 8 hours</time_frame>
    <description>To learn if opioid consumption is reduced when IV acetaminophen is provided immediately post-operatively.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total Time in Post Anesthesia Care Unit (PACU) (or &quot;Recovery Room&quot;)</measure>
    <time_frame>up to 8.6 hours</time_frame>
    <description>To ascertain if the total time the participant remains in the PACU (from admission to discharge) differs between those who received IV acetaminophen versus those who do not receive IV acetaminophen.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Intravenous acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of Intravenous acetaminophen (Ofirmev)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (0.9% Normal Saline Infusion)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of 100 ml of 0.9 NS Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Acetaminophen</intervention_name>
    <description>Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.</description>
    <arm_group_label>Intravenous acetaminophen</arm_group_label>
    <other_name>Ofirmev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.9% Normal Saline infusion)</intervention_name>
    <description>Infusion of 100 ml of 0.9% NS</description>
    <arm_group_label>Placebo (0.9% Normal Saline Infusion)</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is scheduled for knee arthroscopy with or without chondroplasty.&#xD;
&#xD;
          -  Scheduled arthroscopy procedure will not include ligament repairs or ligament&#xD;
             reconstructions and/or bone cutting or fixation procedures.&#xD;
&#xD;
          -  Has not received any acetaminophen (IV, PR, PO) within at least 8 hours of the&#xD;
             initiation of surgery.&#xD;
&#xD;
          -  Is willing and able to sign an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is undergoing arthroscopy for ligament repairs/reconstructions and bone cutting or&#xD;
             fixation procedures&#xD;
&#xD;
          -  Has self-reported and/or documented previous hypersensitivity to acetaminophen.&#xD;
&#xD;
          -  Has self-reported and/or documented history of hepatic disease or impairment.&#xD;
&#xD;
          -  Pre-operative calculated creatinine clearance (CrCL) less than 40 ml/min.&#xD;
&#xD;
          -  Has a medical history of alcohol abuse and/or currently drinks more than 3 alcoholic&#xD;
             beverages per day.&#xD;
&#xD;
          -  Has a medical history of substance dependence (i.e. prescription analgesics or illegal&#xD;
             drugs such as cocaine, heroin, etcâ€¦). May be self-reported or maybe per the judgment&#xD;
             of the physician PI/Sub-I.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Homan, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital Celebration Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Hospital Celebration Health</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <zip>34747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 30, 2013</study_first_submitted>
  <study_first_submitted_qc>December 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2014</study_first_posted>
  <results_first_submitted>September 30, 2020</results_first_submitted>
  <results_first_submitted_qc>October 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2020</results_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain, Postoperative</keyword>
  <keyword>Ofirmev</keyword>
  <keyword>Acetaminophen</keyword>
  <keyword>Analgesics, Non-Narcotic</keyword>
  <keyword>Arthroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Acetaminophen</title>
          <description>Infusion of Intravenous acetaminophen (Ofirmev)&#xD;
Intravenous Acetaminophen: Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (0.9% Normal Saline Infusion)</title>
          <description>Infusion of 100 ml of 0.9 NS Normal Saline&#xD;
Placebo (0.9% Normal Saline infusion): Infusion of 100 ml of 0.9% NS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Acetaminophen</title>
          <description>Infusion of Intravenous acetaminophen (Ofirmev)&#xD;
Intravenous Acetaminophen: Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (0.9% Normal Saline Infusion)</title>
          <description>Infusion of 100 ml of 0.9 NS Normal Saline&#xD;
Placebo (0.9% Normal Saline infusion): Infusion of 100 ml of 0.9% NS</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="54"/>
                    <count group_id="B3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="54"/>
                    <count group_id="B3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Pain Levels</title>
        <description>To determine if postoperative pain levels, as measured by a Verbal Numerical Rating Scale (VNRS), are reduced with the administration of IV acetaminophen when compared to a control group. In the VNRS, the user has the option to verbally rate their scale from 0 to 10. Zero indicates the absence of pain, while 10 represents the most intense pain possible.</description>
        <time_frame>up to 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Acetaminophen</title>
            <description>Infusion of Intravenous acetaminophen (Ofirmev)&#xD;
Intravenous Acetaminophen: Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (0.9% Normal Saline Infusion)</title>
            <description>Infusion of 100 ml of 0.9 NS Normal Saline&#xD;
Placebo (0.9% Normal Saline infusion): Infusion of 100 ml of 0.9% NS</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain Levels</title>
          <description>To determine if postoperative pain levels, as measured by a Verbal Numerical Rating Scale (VNRS), are reduced with the administration of IV acetaminophen when compared to a control group. In the VNRS, the user has the option to verbally rate their scale from 0 to 10. Zero indicates the absence of pain, while 10 represents the most intense pain possible.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3160" spread="1.33510"/>
                    <measurement group_id="O2" value="2.1362" spread="1.59323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Opioid Consumption</title>
        <description>To learn if opioid consumption is reduced when IV acetaminophen is provided immediately post-operatively.</description>
        <time_frame>up to 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Acetaminophen</title>
            <description>Infusion of Intravenous acetaminophen (Ofirmev)&#xD;
Intravenous Acetaminophen: Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (0.9% Normal Saline Infusion)</title>
            <description>Infusion of 100 ml of 0.9 NS Normal Saline&#xD;
Placebo (0.9% Normal Saline infusion): Infusion of 100 ml of 0.9% NS</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Opioid Consumption</title>
          <description>To learn if opioid consumption is reduced when IV acetaminophen is provided immediately post-operatively.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="50"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Time in Post Anesthesia Care Unit (PACU) (or &quot;Recovery Room&quot;)</title>
        <description>To ascertain if the total time the participant remains in the PACU (from admission to discharge) differs between those who received IV acetaminophen versus those who do not receive IV acetaminophen.</description>
        <time_frame>up to 8.6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Acetaminophen</title>
            <description>Infusion of Intravenous acetaminophen (Ofirmev)&#xD;
Intravenous Acetaminophen: Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (0.9% Normal Saline Infusion)</title>
            <description>Infusion of 100 ml of 0.9 NS Normal Saline&#xD;
Placebo (0.9% Normal Saline infusion): Infusion of 100 ml of 0.9% NS</description>
          </group>
        </group_list>
        <measure>
          <title>Total Time in Post Anesthesia Care Unit (PACU) (or &quot;Recovery Room&quot;)</title>
          <description>To ascertain if the total time the participant remains in the PACU (from admission to discharge) differs between those who received IV acetaminophen versus those who do not receive IV acetaminophen.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" lower_limit="1.08" upper_limit="5.22"/>
                    <measurement group_id="O2" value="3.40" lower_limit="1.23" upper_limit="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Acetaminophen</title>
          <description>Infusion of Intravenous acetaminophen (Ofirmev)&#xD;
Intravenous Acetaminophen: Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (0.9% Normal Saline Infusion)</title>
          <description>Infusion of 100 ml of 0.9 NS Normal Saline&#xD;
Placebo (0.9% Normal Saline infusion): Infusion of 100 ml of 0.9% NS</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brad Homan</name_or_title>
      <organization>AdventHealth</organization>
      <phone>407-303-4270</phone>
      <email>Brad.Homan.MD@AdventHealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

